Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2010 - 2026)

Jazz Pharmaceuticals' Capital Expenditures history runs 17 years deep, the most recent figure standing at $77.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 455.4% year-over-year to $77.2 million; the TTM figure through Mar 2026 stood at $122.1 million (up 1644.6% YoY), while the FY2025 annual figure was $58.8 million, changed N/A from the prior year.
• Capital Expenditures was $77.2 million for Q1 2026 at Jazz Pharmaceuticals, up from $16.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $844.2 million in Q2 2025 to a low of -$816.0 million in Q3 2025.
• Historically, Capital Expenditures has averaged $11.8 million across 5 years, with a median of $8.2 million in 2022.
• Biggest YoY gain for Capital Expenditures was 11804.57% in 2025; the steepest drop was 5730.87% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $9.4 million in 2022, then advanced by 7.72% to $10.1 million in 2023, then slumped by 238.54% to -$14.0 million in 2024, then jumped by 219.54% to $16.7 million in 2025, then jumped by 361.47% to $77.2 million in 2026.
• The last three Capital Expenditures figures came in at $77.2 million (Q1 2026), $16.7 million (Q4 2025), and -$816.0 million (Q3 2025), per Business Quant data.